FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy

Abstract

Abstract Background 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) is a method of imaging that assesses and measures metabolic avidity in cancer cells, acting as a proxy for underlying cellular activity and vitality and so providing anatomic and metabolic information. 18F-FDG PET-CT is beneficial for detecting local recurrence, distant metastases, and monitoring tumor viability after chemotherapy and radiotherapy in patients with colorectal cancer. Strict adherence to set protocols, technological processes, and good patient preparation are essential to produce the greatest results. The goal of the trial was to see how useful PET/CT was in following up on patients who had resected colorectal cancer and had completed adjuvant chemotherapy rounds. Results In this study, PET/CT early detected hepatic deposits, pulmonary masses, bone deposits, and sizable LNs. PET/CT provided useful information and had a considerable impact on disease management, enabling the detection of recurrent disease as early as possible with high accuracy in assessment of therapeutic response. It detected viable residual tumor cells in operative bed scar, small metabolically active LNs, hepatic focal lesions, peritoneal deposits, pulmonary secondaries, and bone deposits avoiding unnecessary surgeries. Conclusion Because of its high accuracy in detection and capacity to identify recurrent illness, FDG-PET-CT imaging is effective in evaluating post-therapeutic colorectal cancer patients with suspected tumor recurrence or distant metastases.

Keywords

• FDG PET/CT
• Colorectal carcinoma
• Adjuvant chemotherapy